When was Genable Technologies founded?

Genable Technologies was founded in 2001 and raised its 1st funding round 3 years after it was founded.

Where is Genable Technologies located?

Genable Technologies is headquartered in Dublin, Ireland.

Is Genable Technologies a funded company?

Genable Technologies is a funded company, having raised a total of $8.11M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 07, 2004.

When was the latest funding round of Genable Technologies?

Genable Technologies' latest funding was a $***** Series B round on Nov 11, 2011, with participation from 2 investors. Its primary sector is Genomics. In Ireland, the Genomics sector has seen $39M in funding in 2026 to date.

Where does Genable Technologies rank among its competitors?

Genable Technologies ranks 1127th amongst 3076 active competitors, of which 1068 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Genable Technologies?

Genable Technologies' top competitors include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Among them, Karyopharm secured the most recent funding round in March, 2026.

Genable Technologies - 2026 Company Profile, Team, Funding & Competitors

Genable Technologies is an acquired company based in Dublin (Ireland), founded in 2001 by Jane Farrar and Paul Kenna. It operates as a Provider of gene therapy to treat Retinitis pigmentosa. Genable Technologies has raised $8.11M in funding. The company has 3076 active competitors, including 1068 funded and 767 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alnylam and Sana Biotechnology.

Company Details

Provider of gene therapy to treat Retinitis pigmentosa. The first gene medicine - RhoNova formerly known as GT038 - is for the treatment of patients with rhodopsin (RHO)-linked adRP - a debilitating form of inherited blindness resulting from a diverse array of mutations in the RHO gene. It utilizes AAV vectors to obtain expression of RNA interference (RNAi) molecules which suppress the expression of both the faulty and normal gene copies and replaces this with a gene subtly altered to become refractory to suppression but still encoding a normal wild type protein.

Key Metrics

Founded Year

2001

Location

Dublin, Ireland

Stage

Acquired

Total Funding

$8.11M in 2 rounds

Latest Funding Round

Series B, Nov 11, 2011, $*****

Investors

Furthr & 2 more

Ranked

1127^th among 3076 active competitors

Similar Companies

Alnylam & 960 more

Exit Details

Acquired by Spark Therapeutics (Mar 07, 2016)

View Genable Technologies' full profile

Genable Technologies got acquired by Spark Therapeutics on Mar 07, 2016 at an acquisition amount of $*****.

Click here to take a look at Genable Technologies's acquisition in detail

Genable Technologies has raised a total funding of $8.11M over 2 rounds. Its first funding round was on Sep 07, 2004. Its latest funding round was a Series B round on Nov 11, 2011 for $*****. 2 investors participated in its latest round. Genable Technologies has 3 institutional investors.

Here is the list of recent funding rounds of Genable Technologies:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 11, 2011	1709229	Series B	1866339	7661398	5259338	1911022
Sep 07, 2004	1756418	Series A	2709026	5650566	5225823	Delta Partners

Access funding benchmarks and valuations. Sign up today!

View details of Genable Technologies's funding rounds and investors

The founders of Genable Technologies are Jane Farrar and Paul Kenna.

Here are the details of Genable Technologies' key team members:

Jane Farrar: Co-Founder of Genable Technologies.
Paul Kenna: Co-Founder of Genable Technologies.

View details of Genable Technologies's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Genable Technologies include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of Genable Technologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
1127th	Genable Technologies 2001, Dublin (Ireland), Acquired	Provider of gene therapy to treat Retinitis pigmentosa	$8.11M	Furthr, Delta Partners & 1 others	39/100